Loading...
  • lesions
  • Vaccine efficacy against CIN2+ associated with HPV-16/18 was 92.9% (96.1% CI 79.9-98.3) in the primary analysis and 98.1% (88.4-100) in an analysis in which probable causality to HPV type was assigned in lesions infected with multiple oncogenic types (ATP-E cohort). (nih.gov)
  • Vaccine efficacy against CIN2+ irrespective of HPV DNA in lesions was 30.4% (16.4-42.1) in the TVC and 70.2% (54.7-80.9) in the TVC-naive. (nih.gov)
  • TORONTO, July 7 -- A vaccine against two oncogenic strains of human papillomavirus (HPV) is highly effective at preventing the lesions that lead to cervical cancer, researchers said. (medpagetoday.com)
  • For CIN3, there were two cases of HPV-16-associated lesions in the vaccine arm and 10 in the control group, the researchers found. (medpagetoday.com)
  • One major "unavoidable" limitation, they said, was that the high efficacy of the vaccine meant that more women in the control group than in the vaccine group were referred for colposcopy, which might have resulted in case ascertainment bias for detection of lesions associated with nonvaccine types. (medpagetoday.com)
  • The vaccines have an excellent safety profile, are highly immunogenic, and have conferred complete type-specific protection against persistent infection and associated lesions in fully vaccinated women. (nih.gov)
  • Immunohistochemical analysis of CD4+ and CD8+ T-cell subsets in high risk human papillomavirus-associated pre-malignant and malignant lesions of the uterine cervix. (nih.gov)
  • In addition, the data demonstrated that the vaccine also provided type-specific protection against pre-cancerous lesions associated with some additional common cancer-causing HPV types other than HPV 16 and HPV 18. (centerwatch.com)
  • In large phase III trials, the vaccine prevented 100% of moderate and severe precancerous cervical lesions associated with types 16 or 18 among women with no previous infection with these types. (scielosp.org)
  • Among men and women, cancers of the ano-genital tract and their precursor lesions have been strongly linked to infection with sexually transmited human papillomavirus. (intechopen.com)
  • immunotherapy
  • Perspectives for the development of human papillomavirus vaccines and immunotherapy. (nih.gov)
  • Most recently, published in July of 2004 in Cancer Immunology, Immunotherapy , researchers tested the immunogenicity of a fusion protein (PD-E7) comprised of a mutated HPV-16 E7 linked to part of the Haemophilus influenzae protein D. This vaccine was given to seven patients with HPV-associated CIN. (oncolink.org)
  • clinical
  • The paradigm of preventing HPV infection through vaccination has been tested, and two vaccines are currently in phase III clinical trials. (unboundmedicine.com)
  • In November of 2003, Clinical Cancer Research published a study of 12 women with high-grade HPV-associated vulval or vaginal intraepithelial neoplasias who were immunized with a recombinant TA-HPV modified vaccine, similar to the vaccine used in the above study. (oncolink.org)
  • Although the results of clinical trials investigating HPV vaccines have been promising, several limitations need to be overcome before cervical cancer can potentially be eradicated worldwide. (oncolink.org)
  • nonvaccine
  • Many women in the study were infected with nonvaccine oncogenic strains of HPV, and in a post hoc analysis, the researchers estimated a cross-protective efficacy that could represent between 11% and 16% additional protection against cervical cancer. (medpagetoday.com)
  • capsid
  • Papillomavirus has only two capsid proteins, L1 and L2. (hopkinsmedicine.org)
  • It is thought that the efficacy of the vaccine may be mediated by the development of IgG neutralizing antibodies directed against HPV-L1 capsid proteins generated as a result of vaccination. (centerwatch.com)
  • However, because the capsid proteins are not expressed at detectable levels by infected basal keratinocytes or in HPV-transformed cells, a second approach of developing therapeutic vaccines by targeting nonstructural early viral antigens has also been developed. (unboundmedicine.com)
  • trials
  • This article critically reviews HPV vaccine serious adverse events described in pre-licensure randomized trials and in post-marketing case series. (springer.com)
  • HPV vaccine randomized trials were identified in PubMed. (springer.com)
  • Two of the largest randomized trials found significantly more severe adverse events in the tested HPV vaccine arm of the study. (springer.com)
  • In limited trials, a vaccine has demonstrated efficacy in preventing both HPV-16 infection and HPV-related cervical intraepithelial neoplasia in women not previously exposed to the virus. (thefreedictionary.com)
  • baseline
  • The primary endpoint was to assess vaccine efficacy against cervical intraepithelial neoplasia 2+ (CIN2+) that was associated with HPV-16 or HPV-18 in women who were seronegative at baseline, and DNA negative at baseline and month 6 for the corresponding type (ATP-E). This trial is registered with ClinicalTrials.gov, number NCT00122681 . (nih.gov)
  • The primary endpoint was vaccine efficacy against CIN2 (or higher grade) associated with HPV-16 or -18 in women who were not infected with either at baseline, and who got all three injections of the vaccine. (medpagetoday.com)
  • Results Samples from 404/2185 (18.5% (95% CI 16.9% to 20.2%)) of the cohort were positive for carcinogenic HPV at baseline, including 15.0% (327) positive for non-vaccine carcinogenic genotypes. (bmj.com)
  • Responses
  • Our vaccine is based on a single molecule, is highly thermostable and more importantly, induces protective responses against all oncogenic HPV as well as a number of so called low risk HPV. (dkfz.de)
  • Hanna Seitz, Elena Canali, Lis Ribeiro-M ller, Anik Palfi, Angelo Bolchi, Massimo Tommasino, Simone Ottonello, Martin M ller (2014) A three component mix of thioredoxin-L2 antigens elicits broadly neutralizing responses against oncogenic human papillomaviruses. (dkfz.de)
  • Diseases
  • This report published in Communicable Diseases Intelligence, Volume 28, Number 2 discusses human papillomavirus (HPV) which is the most common viral sexually transmitted infection, with estimates that up to 75 per cent of people are infected at some time. (health.gov.au)
  • With a view to initiating discussion and research into the possible future role of HPV vaccines in Australia, on 12 December 2003, the National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases brought together representatives from eight Australian research groups currently involved in HPV research and both vaccine manufacturers with current HPV vaccine candidates. (health.gov.au)
  • This report summarizes the epidemiology of HPV and associated diseases, describes the licensed HPV vaccine, and provides recommendations for its use for vaccination among females aged 9--26 years in the United States. (cdc.gov)
  • A population-based study of vaginal human papillomavirus infection in hysterectomized women," Journal of Infectious Diseases , vol. 190, no. 3, pp. 458-467, 2004. (hindawi.com)